Rating History
Dissemination Date Long-Term Rating Short-Term Rating Outlook Action Rating Watch
16-May-25 A+ A1 Stable Maintain -
17-May-24 A+ A1 Stable Maintain -
17-May-23 A+ A1 Stable Maintain -
17-May-22 A+ A1 Stable Upgrade -
01-Jul-21 A A1 Positive Maintain -
About the Entity

Descon Oxychem Limited, incorporated in 2004, commenced commercial production of Hydrogen Peroxide in March 2009. Descon Group, the principal sponsor of Descon Oxychem, holds a majority shareholding of 72.63% through associated companies, while 27.37% stake rests with financial institutions and the general public. Descon Group has a strong foothold in the engineering business through its flagship company – Descon Engineering Limited. The Company’s Board, comprising eight members, is dominated by representatives of Descon Group. Mr. Faisal Dawood is the Chairman of the Board, while Mr. Muhammad Mohsin Zia is the CEO of the Company.

Rating Rationale

Descon Oxychem Limited (‘DOL’ or ‘the Company’), a listed concern, is primarily engaged in the manufacturing, procurement, and sale of Hydrogen Peroxide (HPO) & allied products. Offering Technical, Aseptic, and Food Grades in different concentrations, DOL’s diverse HPO applications span key sectors including textile, mining, pulp & paper, water treatment, sugar, food & beverages, cosmetics, and poultry. The Company’s leading market position is supported by a strong sponsorship and established client relationships. Notably, its sustainable, non-chlorine-based food-grade HPO offers substantial growth prospects within the food sector, requiring focused strategic development. Within Pakistan’s competitive HPO market, local supply is dominated by domestic production of ~80.0%, with imports making up the remaining ~20.0%. Market growth in FY24 was solely attributable to a ~14% increase in imported HPO volume, as local capacity remained stable and fully utilized. However, the market’s evolving dynamics are expected to be further reshaped by the arrival of a new player (Engro Peroxide), leading to anticipated shifts in demand and supply patterns in CY25, specifically in the South region. During 1HFY25, DOL’s topline exhibited modest improvement, reaching ~PKR 3,197mln, representing a marginal year-over-year growth of 11.4%, attributable to a price increase. However, the Company’s export revenue has trended downwards, registering ~PKR 176mln in 1HFY25 (FY24: PKR 419mln, FY23: PKR 643mln), owing to the closure of routes to Commonwealth of Independent States (CIS) markets, but the impact has been neutralized by a shift towards local sales. During 1HFY25, the profitability matrix of the Company improved at all levels on the back of price and cost efficiencies. Looking ahead, a new entrant in the local market necessitates a proactive focus on the business strategy, sales growth, and profitability. Management indicates a strategic initiative to broaden its customer base in international markets, including the UAE, KSA, Bahrain, and Ashgabat. Historically, DOL has successfully expanded its revenue base through investments in advanced technology, efficient production processes, and a focus on higher-margin regions and segments. The financial risk profile of the Company remains good, characterized by efficient working capital management and healthy coverages. DOL’s capital structure is low-leveraged, comprising a mix of long-term and short-term borrowings supported by a solid equity base. Ratings draw comfort from DOL’s association with the financially sound and experienced business group - DESCON. Going forward, the Company will enhance production capacity to leverage economies of scale and expand its presence in the competitive market.

Key Rating Drivers

The ratings are dependent on the DOL’s ability to sustain its position in a competitive environment and management’s ability to execute strategies to capitalize on new opportunities. With the growth in DOL’s revenue, prudent financial performance and an effective liquidity profile shall remain imperative.

Profile
Legal Structure

Descon Oxychem Limited (hereinafter referred to as “Descon Oxychem” or “the Company”) is a public listed entity incorporated under the Companies Ordinance, 1984 (now “Companies Act, 2017”). Its registered office is located at 18-KM Ferozepur Road, Lahore.


Background

Descon Oxychem was incorporated as a private limited company in 2004 and was listed on September 15, 2008. It is a project of the Descon Group. The Company is a subsidiary of DEL Chemicals (Private) Limited (the parent company), an unlisted private company incorporated in Pakistan. Following commissioning in October 2008, the Company’s plant started commercial production in March 2009. The Company has also incorporated a wholly owned subsidiary, “Descon Oxychem FZE” in Hamriyah Free Zone, Sharjah, UAE, that is engaged in import, export, and trading of chemicals & related products, detergents & disinfectants, water treatment & purification chemicals, and raw materials.


Operations

The prime business of Descon Oxychem is the manufacturing & distribution of Hydrogen Peroxide (HPO) of up to 60% concentration. Descon Oxychem has launched its brands for different grades of Hydrogen Peroxide with different concentration levels including: i) Technical Grade, ii) Aseptic Grade, and iii) Food Grade. Its production facility is located at 18-KM Lahore Sheikhupura Road, consisting of an HPO plant with a capacity of ~42,000 MT per annum at ~100% concentration and a Hydrogen plant. The Hydrogen plant, is capable of producing hydrogen sufficient for two-fold expansion of HPO facility. Descon Oxychem has technical collaboration with Chematur Engineering Sweden, a well-known engineering firm that has delivered more than 1,100 different chemical industrial plants worldwide. It has provided detailed engineering for construction of HPO plant to Descon Engineering Limited (Flagship Company of the Descon Group) and assisted in the plant’s commissioning.


Ownership
Ownership Structure

The principal sponsor of Descon Oxychem holds a majority shareholding of ~72.63% through associated companies while the remaining ~27.37% stake rests with the financial institutions and the general public. 


Stability

The transfer of the Company's ownership to a holding company provides clarity to Descon Oxychem’s ownership structure, boding well for its stability.


Business Acumen

Originating from Pakistan, the Descon Group has, over the years, expanded its horizons to Abu Dhabi, Saudi Arabia, Qatar, Oman and Egypt. With presence in the chemical sector since 1980, Descon Oxychem is well placed to benefit from the Group’s technical knowledge, vast distribution network and established relationship with clients. Mr. Abdul Razak Dawood, former Advisor to Ex-Prime Minister Imran Khan for Commerce, Textile, Industry and Production of Pakistan, was founder and former Chairman of the Descon Group. Now, Mr. Taimur Dawood, son of Mr. Abdul Razak Dawood, leads the Group. The Dawoods are one of the well-known business families of the country and known for their business acumen.


Financial Strength

Descon Group has expanded its footing in diversified business avenues with a sizable portfolio of strategic investments, enhancing the Group’s financial strength. Its business portfolio spans across various sectors including engineering, power and chemicals. The Group aims for sustainable profitability of its business ventures while expanding its outreach globally through timely exploitation of business opportunities. The Group has shown willingness and ability to support the Group companies in times of need. 


Governance
Board Structure

The Company’s board comprises eight members including five non-executive, two independent directors, and one executive who also serves as the CEO. Descon Oxychem's board structure is considered strong.


Members’ Profile

Descon Oxychem’s board comprises highly qualified members and has a blend of business studies, engineering, and finance professionals. The Chairman, Mr. Faisal Dawood holds a Bachelors degree in Materials Science and Engineering from Cornwell University and an MBA from Columbia University. He has served at multiple management positions within the engineering and chemical divisions of the Descon Group and currently also serves as the Vice-Chairman of Descon Engineering. Furthermore, Mr. Taimur Dawood has over 20 years of diversified experience in engineering, product marketing, project finance, strategy development and implementation and mergers and acquisitions. He is serving as Chairman of other Descon Group companies including Descon Engineering Limited and Descon Power Solutions (Pvt.) Limited. He is also the Managing Director of Gray Mackenzie Engineering Services BV, the Netherlands. From 2001 to 2011, Mr. Taimur served as the CEO of Descon Chemicals. The other directors of the Company hold senior positions in associated companies and serve on the Boards of other Group companies. They further strengthen the Board with their diverse professional backgrounds and extensive expertise.


Board Effectiveness

Meeting agendas provided to Board members and documentation of meeting minutes remain strong. The Board further ensures effective governance through four committees, namely: i) Enterprise Risk Management Committee, ii) Audit Committee, iii) Human Resource & Remuneration Committee and iv) Compliance Committee. The Audit Committee is chaired by a non-executive Director. The Board also ensures strong monitoring and control through monthly meetings with management – conducted by nominated Board members. Prior to this meeting, MIS reports are sent to all Board members and a thorough discussion is held on key performance areas. This bodes well for the Board’s effectiveness.


Financial Transparency

M/s Crowe Hussain Chaudhury & Co., listed in Category “A” of the State Bank’s panel of auditors, is the external auditor of the Company. The auditors have reviewed the Company’s financial statements for the period ended December 31, 2024. Meanwhile, public disclosures remain strong. The Company has outsourced its internal audit function to KPMG Taseer Hadi & Co., also listed in Category “A” of the State Bank’s panel of auditors.


Management
Organizational Structure

The Company operates through seven functional departments, each headed by an experienced manager. The departments include: i) Plant Management, ii) Investments, iii) Marketing & Sales – North & South, iv) Finance & Accounts, v) Human Resource, vi) Quality & Assurance and vii) Sourcing & Planning. All departmentheads/managers’ report directly to the CEO. In order to rationalize costs some business functions (IT, HR and Accounting & Finance) are shared at Group level. Currently, all key positions within the organization are fully staffed, reflecting the Company’s commitment to maintaining a robust and efficient workforce.


Management Team

Mr. Muhammad Mohsin Zia is currently serving as the CEO of Descon Oxychem. Mr. Mohsin was appointed during April, 2021. He brings with him 28 years of diverse experience in Marketing Services, Business Development, Sales Management, Supply Chain Management and Strategy, development. Previously, Mr. Mohsin was working as General Manager & BU Head Pakistan- Construction Chemicals at BASF Pakistan. Mr. Mohsin has also worked at various other roles like Head of Supply Chain, Business Unit Head & Deputy Head of Operations for South Asia, and Head of Corporate Strategy and has got extensive exposure in Strategy Development, Marketing & Sales, Business Development Projects, & New Venture Planning and Development. He holds an MBA degree from Institute of Business Administration, Karachi. He is assisted by a team of  experienced and seasoned professionals including the CFO, Ms. Rabia Shoaib, a qualified Chartered Accountant and joined the Descon Group in 2022. With over 18 years of experience across multiple finance domains, she brings expertise in project control, stakeholder management, and financial operations.


Effectiveness

Descon Oxychem’s senior management receives daily performance reports of the plant’s operations which results in optimal monitoring. While there are no formal management committees, key management personnel meet on daily and weekly basis to discuss key issues. Furthermore, there are regular need-based meetings for discussion of issues.


MIS

The Company has implemented R12 version of the Oracle E-business suite application, which is also used at other associated companies of Descon. The ERP solution is capable of generating various MIS related to production, inventory management, sales and trade receivables/payables. Oracle Financials, Manufacturing and Projects modules have been completely implemented. The implementation of the ERP system further strengthens the control environment of the Company due to in-built controls of the system, in addition to better reporting and increased efficiency due to automation of the business processes.


Control Environment

Hydrogen peroxide (H2O2) is a relatively new product for the domestic chemical sector and owing to the initial setup arrangements with Chematur Engineering, Sweden; the technical specifications of Descon Oxychem’s plant are sound. Regular visits by Chematur’s staff also ensure efficient capacity utilization and quality of final product. Descon Oxychem has been given the license to be sole operator of Chematur technology in Pakistan. The plant is highly automated and is operated by DCS (Digital Control System). It assists management in controlling and monitoring the production process and chemical levels. To improve operational reliability Descon Oxychem has built organizational capacity by implementing Quality hygiene Safety Model and Reliability Centre Management. Introduction of Reliability Centre Management has changed the perspective of Company’s operation from fix it culture to run it culture. This culture has helped Descon Oxychem to improve plant reliability significantly.


Business Risk
Industry Dynamics

Pakistan’s HPO industry presently consists of two players: i) Descon Oxychem & ii) Sitara Peroxide, each with an installed capacity of ~42,000MT & ~30,000MT, respectively (at 50pc concentration). However, the Sitara Peroxide plant remained shut down from October 20, 2022 to March 02, 2023 and then again from June 12, 2023 to date. Currently, the domestic demand outstrips the supply and ~20% of local demand is met through imports. Major consumer of HPO is the textile industry, accounting for more than 3/4 of the total domestic demand (70%); this is followed by the mining, paper & board, & food industries. Going forward, Engro Peroxide's HPO plant intends to enter the market with ~28,000MT capacity (at 50pc concentration). Anti-dumping is installed on imports based on foreign manufacturers selling products at significantly lower margins/loss to make the business less sustainable for local players. This is necessary to protect foreign exchange reserves and encourage local industry.


Relative Position

Currently, Descon Oxychem holds a dominant market share exceeding 50% in the HPO sector. However, the recent commissioning of Engro's new plant is anticipated to reshape market share dynamics, particularly in the South region. Despite this increased competition, Descon Oxychem's strong customer base, ongoing expansions, and pursuit of new opportunities position it to likely maintain its leading role in the industry. 


Revenues

The Company derives its revenues principally from local sales (~99%) which is predominant to the textile sector for bleaching & dyeing purposes while the remaining minor portion of sales is made to mining & food sector consumers. During 1HFY25, the top line of the Company has shown a growth of ~11.4% YoY and clocked in at ~PKR 3,197mln (FY24: PKR 5,738mln, FY23: PKR 6,721mln, FY22: ~PKR 4,250mln). This growth is primarily attributed to a volumetric increase.


Margins

The Company’s gross margin showed a significant improvement in 1HFY25 and reported at ~32.0% (FY24: ~20.1%, FY23: ~41.0%). The same translated into a increased operating profit margin (1HFY25: ~25.6%, FY24: ~13.4%, FY23: ~35.3%). Finance cost decreased to PKR 5mln in 1HFY25 from PKR 24mln in FY24. Subsequently, the net margin improved and stood at ~15.5% during 1HFY25 (FY24: ~8.8%, FY23: 20.8%).


Sustainability

Descon Oxychem regularly invests in BMR. Optimal capacity utilization is of utmost importance to manage costs & sustain high margins. Efforts to penetrate new market segments have been successfully implemented alongside organic growth in the Textile, Mining & Food sectors. The company is also exploring other options to diversify into downstream products which will further strengthen the usage of HPO in the local market.


Financial Risk
Working capital

Descon Oxychem’s cash cycle remains robust as nearly all sales are on a cash basis while the Company is offered a credit period of ~90 days by its sourcing partners. Over the period, working capital cycle has stretched over the years which is evident from the gross cash cycle (1HFY25: ~47 days, FY24: ~54 days, FY23: ~37 days) and the net cash cycle reached ~39 days in 1HFY25 (FY24: ~38 days, FY23: ~15 days).


Coverages

The Company’s FCFO clocked in at PKR 873mln in 1HFY25 owing to improved profitability. Consequently, interest coverage ratio improved (1HFY25: ~300.7x, FY24: ~70.7x, FY23: ~235.1x). Its debt coverage ratio also significantly improved in 1HFY25 and recorded at ~49.3x (FY24: ~2.8x, FY23: ~38.0x). 


Capitalization

Descon Oxychem’s leveraging has decreased significantly over the years. During FY21, the Company obtained a long-term loan for the expansion project. Accordingly, leveraging increased to ~36.7% in FY21. However, the same had been reduced to ~13.4% during FY22 and 7.9% during FY23. As at end Dec-24, leveraging further improved to ~5.7%. Long-term loan makes ~51% of the total debt of the Company.


 
 

May-25

www.pacra.com


Dec-24
6M
Jun-24
12M
Jun-23
12M
Jun-22
12M
A. BALANCE SHEET
1. Non-Current Assets 1,882 2,034 2,349 2,546
2. Investments 676 140 897 150
3. Related Party Exposure 0 0 2 0
4. Current Assets 1,934 1,973 1,788 1,209
a. Inventories 535 631 717 249
b. Trade Receivables 320 176 166 237
5. Total Assets 4,493 4,147 5,036 3,905
6. Current Liabilities 696 601 1,506 915
a. Trade Payables 160 129 364 451
7. Borrowings 204 115 261 366
8. Related Party Exposure 0 0 0 0
9. Non-Current Liabilities 231 215 209 265
10. Net Assets 3,361 3,216 3,059 2,359
11. Shareholders' Equity 3,361 3,216 3,059 2,359
B. INCOME STATEMENT
1. Sales 3,197 5,738 6,721 4,250
a. Cost of Good Sold (2,173) (4,584) (3,965) (3,149)
2. Gross Profit 1,024 1,154 2,756 1,102
a. Operating Expenses (206) (384) (383) (201)
3. Operating Profit 818 770 2,373 901
a. Non Operating Income or (Expense) (34) 108 (123) (46)
4. Profit or (Loss) before Interest and Tax 784 878 2,250 855
a. Total Finance Cost (5) (24) (26) (53)
b. Taxation (283) (347) (823) (332)
6. Net Income Or (Loss) 496 507 1,401 471
C. CASH FLOW STATEMENT
a. Free Cash Flows from Operations (FCFO) 873 127 2,374 1,118
b. Net Cash from Operating Activities before Working Capital Changes 868 107 2,345 1,065
c. Changes in Working Capital (33) (132) (474) (9)
1. Net Cash provided by Operating Activities 835 (25) 1,871 1,056
2. Net Cash (Used in) or Available From Investing Activities (600) 748 (905) 20
3. Net Cash (Used in) or Available From Financing Activities (260) (511) (824) (1,027)
4. Net Cash generated or (Used) during the period (25) 213 142 49
D. RATIO ANALYSIS
1. Performance
a. Sales Growth (for the period) 11.4% -14.6% 58.1% 51.5%
b. Gross Profit Margin 32.0% 20.1% 41.0% 25.9%
c. Net Profit Margin 15.5% 8.8% 20.8% 11.1%
d. Cash Conversion Efficiency (FCFO adjusted for Working Capital/Sales) 26.3% -0.1% 28.3% 26.1%
e. Return on Equity [ Net Profit Margin * Asset Turnover * (Total Assets/Shareholders' Equity )] 30.2% 16.1% 51.7% 21.3%
2. Working Capital Management
a. Gross Working Capital (Average Days) 47 54 37 31
b. Net Working Capital (Average Days) 39 38 15 6
c. Current Ratio (Current Assets / Current Liabilities) 2.8 3.3 1.2 1.3
3. Coverages
a. EBITDA / Finance Cost 300.7 70.7 235.1 25.4
b. FCFO / Finance Cost+CMLTB+Excess STB 49.3 2.8 38.0 8.5
c. Debt Payback (Total Borrowings+Excess STB) / (FCFO-Finance Cost) 0.1 1.0 0.1 0.3
4. Capital Structure
a. Total Borrowings / (Total Borrowings+Shareholders' Equity) 5.7% 3.5% 7.9% 13.4%
b. Interest or Markup Payable (Days) 35.1 28.4 10.7 67.6
c. Entity Average Borrowing Rate 3.6% 7.9% 3.8% 7.5%

May-25

www.pacra.com

May-25

www.pacra.com

  1. Rating Team Statements
    1. Rating is just an opinion about the creditworthiness of the entity and does not constitute a recommendation to buy, hold, or sell any security of the entity rated or to buy, hold, or sell the security rated, as the case may be. (Chapter III; 14-3-(x))
    2. Conflict of Interest
      1. The Rating Team or any of their family members have no interest in this rating (Chapter III; 12-2-(j))
      2. PACRA, the analysts involved in the rating process, and members of its rating committee and their family members do not have any conflict of interest relating to the rating done by them (Chapter III; 12-2-(e) & (k))
      3. The analyst is not a substantial shareholder of the customer being rated by PACRA [Annexure F; d-(ii)]
      4. Explanation: for the purpose of the above clause, the term "family members" shall include only those family members who are dependent on the analyst and members of the rating committee.
  2. Restrictions
    1. No director, officer, or employee of PACRA communicates the information acquired by him for use for rating purposes to any other person, except where required under law to do so. (Chapter III; 10-(5))
    2. PACRA does not disclose or discuss with outside parties or make improper use of the non-public information which has come to its knowledge during a business relationship with the customer. (Chapter III; 10-7-(d))
    3. PACRA does not make proposals or recommendations regarding the activities of rated entities that could impact a credit rating of the entity subject to rating. (Chapter III; 10-7-(k))
  3. Conduct of Business
    1. PACRA fulfills its obligations in a fair, efficient, transparent, and ethical manner and renders high standards of services in performing its functions and obligations. (Chapter III; 11-A-(a))
    2. PACRA uses due care in the preparation of this Rating Report. Our information has been obtained from sources we consider to be reliable, but its accuracy or completeness is not guaranteed. PACRA does not, in every instance, independently verify or validate information received in the rating process or in preparing this Rating Report. (Clause 11-(A)(p))
    3. PACRA prohibits its employees and analysts from soliciting money, gifts, or favors from anyone with whom PACRA conducts business. (Chapter III; 11-A-(q))
    4. PACRA ensures before the commencement of the rating process that an analyst or employee has not had a recent employment or other significant business or personal relationship with the rated entity that may cause or may be perceived as causing a conflict of interest. (Chapter III; 11-A-(r))
    5. PACRA maintains the principle of integrity in seeking rating business. (Chapter III; 11-A-(u))
    6. PACRA promptly investigates in the event of misconduct or a breach of the policies, procedures, and controls, and takes appropriate steps to rectify any weaknesses to prevent any recurrence, along with suitable punitive action against the responsible employee(s). (Chapter III; 11-B-(m))
  4. Independence & Conflict of Interest
    1. PACRA receives compensation from the entity being rated or any third party for the rating services it offers. The receipt of this compensation has no influence on PACRA’s opinions or other analytical processes. In all instances, PACRA is committed to preserving the objectivity, integrity, and independence of its ratings. Our relationship is governed by two distinct mandates: i) rating mandate - signed with the entity being rated or issuer of the debt instrument, and ii) fee mandate - signed with the payer, which can be different from the entity.
    2. PACRA does not provide consultancy/advisory services or other services to any of its customers or their associated companies and associated undertakings that are being rated or have been rated by it during the preceding three years, unless it has an adequate mechanism in place ensuring that the provision of such services does not lead to a conflict of interest situation with its rating activities. (Chapter III; 12-2-(d))
    3. PACRA discloses that no shareholder directly or indirectly holding 10% or more of the share capital of PACRA also holds directly or indirectly 10% or more of the share capital of the entity which is subject to rating or the entity which issued the instrument subject to rating by PACRA. (Chapter III; 12-2-(f))
    4. PACRA ensures that the rating assigned to an entity or instrument is not affected by the existence of a business relationship between PACRA and the entity or any other party, or the non-existence of such a relationship. (Chapter III; 12-2-(i))
    5. PACRA ensures that the analysts or any of their family members shall not buy, sell, or engage in any transaction in any security which falls in the analyst’s area of primary analytical responsibility. This clause, however, does not apply to investments in securities through collective investment schemes. (Chapter III; 12-2-(l))
    6. PACRA has established policies and procedures governing investments and trading in securities by its employees and for monitoring the same to prevent insider trading, market manipulation, or any other market abuse. (Chapter III; 11-B-(g))
  5. Monitoring and Review
    1. PACRA monitors all the outstanding ratings continuously, and any potential change therein due to any event associated with the issuer, the security arrangement, the industry, etc., is disseminated to the market immediately and in an effective manner after appropriate consultation with the entity/issuer. (Chapter III; 17-(a))
    2. PACRA reviews all the outstanding ratings periodically on an annual basis. Provided that public dissemination of annual review and in an instance of change in rating will be made. (Chapter III; 17-(b))
    3. PACRA initiates an immediate review of the outstanding rating upon becoming aware of any information that may reasonably be expected to result in downgrading of the rating. (Chapter III; 17-(c))
    4. PACRA engages with the issuer and the debt securities trustee to remain updated on all information pertaining to the rating of the entity/instrument. (Chapter III; 17-(d))
  6. Probability of Default
    1. PACRA’s Rating Scale reflects the expectation of credit risk. The highest rating has the lowest relative likelihood of default (i.e., probability). PACRA’s transition studies capture the historical performance behavior of a specific rating notch. Transition behavior of the assigned rating can be obtained from PACRA’s Transition Study available at our website. (www.pacra.com) However, the actual transition of rating may not follow the pattern observed in the past. (Chapter III; 14-3(f)(vii))
  7. Proprietary Information
    1. All information contained herein is considered proprietary by PACRA. Hence, none of the information in this document can be copied or otherwise reproduced, stored, or disseminated in whole or in part in any form or by any means whatsoever by any person without PACRA’s prior written consent.

May-25

www.pacra.com